Advertisement

Topics

PlaqueTec Ltd. Company Profile

11:59 EST 17th November 2018 | BioPortfolio

PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory risk. It has been proven to detect inflammatory molecules across the site of coronary artery disease (CAD), and can discriminate between patients with greater and lesser levels of coronary inflammation. PlaqueTec has validated numerous biomarkers that are associated with CAD, and is building the first and only definitive database of cardiovascular disease biology to identify patients at highest risk of heart attack.


News Articles [4 Associated News Articles listed on BioPortfolio]

PlaqueTec sets up new science base at Babraham Research campus in Cambridge

The company has also expanded its headquarters and device development facilities, which are now located in Cambourne Business Park, also in Cambridge. PlaqueTec is leading biomarker-based cardiovascul...

PlaqueTec Sponsors and Presents Data at Vulnerable Patient Meeting

Distinguished faculty of about 75-100 global cardiology leaders meet by invitation only to advance the study and practice of atherosclerosis PlaqueTec announced today that it ...

PlaqueTec Establishes New Science Base at the Babraham Research Campus

PlaqueTec Ltd. has relocated its existing coronary plasma bank from Royal Papworth Hospital to the communal laboratory facility within the Babraham Research Campus in Cambridge. ...

PlaqueTec Data Presented at EAS Show Lack of Correlation between Localised Coronary Artery Inflammatory Biomarker Expression and Systemic Elevation of Biomarkers including hsCRP

Analysis of intracoronary blood samples obtained via PlaqueTec’s Liquid Biopsy System suggests coronary inflammation may be independent of systemic inflammatory biomarkers ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling

This interventional study is using the PlaqueTec LBS will enrol participants already undergoing coronary angiography as a component of their standard care for NSTE-ACS. The study will invo...

Companies [1 Associated Companies listed on BioPortfolio]

PlaqueTec Ltd.

PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory ris...

More Information about "PlaqueTec Ltd." on BioPortfolio

We have published hundreds of PlaqueTec Ltd. news stories on BioPortfolio along with dozens of PlaqueTec Ltd. Clinical Trials and PubMed Articles about PlaqueTec Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PlaqueTec Ltd. Companies in our database. You can also find out about relevant PlaqueTec Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record